Genprex initiated with a Buy at Dawson James

Dawson James analyst Jason Kolbert initiated coverage of Genprex with a Buy rating and $3 price target. The company’s oncology platform utilizes a non-viral Nanoparticle Delivery System and its lead program in oncology, REQORSA Immunogene Therapy, or GPX-001, has been shown to be complementary with targeted drugs and immunotherapies, the analyst tells investors in a research note. REQORSA is currently enrolling clinical patients in two trials initially exploring its utility in NSCLC with a range of agents and the FDA has granted Fast Track Designation for both trials, the firm noted. The company also has developed a gene therapy that is designed to transform alpha cells in the pancreas into functional beta-like cells and its planned phase 1 trial "represents the first-ever gene therapy tested in humans for diabetes," Dawson James said.